乳腺・内分泌外科学分野｜群馬大学大学院医学系研究科総合外科学講座

---

---

乳癌は女性の癌で罹患率が1990年代から部位別罹患率は第1位であり、いまだ増加の一途をたどっています。特に発症年齢も他臓器の癌と異なり、40-60歳代に発症のピークがあり、社会的にも重要な癌であります。乳腺・内分泌外科分野では、乳癌をはじめとする乳腺疾患、甲状腺疾患、上皮小体（副甲状腺）疾患の診断、治療をおこなっています。特に乳癌においては、現在の日本乳癌学会の前身となる乳癌研究会の時代から、学術集会の主催や乳癌取り扱い規約の刊行に関わるなど、日本の乳癌診療において中心的な役割を果たしてきています。研究面では、乳癌の薬物感受性や予後因子の解析を中心に行っており、世界に通じる研究を推進しています。世の中や時代のニーズに対応すべく、外科医の枠にとどまらない、一流のオンコロジストを目指すスタッフを随時募集しています。

研究

|　主な研究テーマ

• 乳癌診療におけるFDG-PETの有用性
• 甲状腺癌のリンパ節転移様式の検討
• 整容性を考慮した乳房再建術
• 甲状腺癌における分子標的薬の有用性と有害事象の検討
• 上皮小体および乳癌センチネルリンパ節同定におけるナビゲーションサージャリー
• 乳癌化学療法有害事象の前向き観察研究

• 腫瘍血管新生のメカニズム解明
• 乳癌治療薬の感受性、バイオマーカー同定
• 乳癌におけるTumor infiltrating lymphocytesの意義
• 乳癌におけるmicroRNAを中心にした網羅的解析
• リンパ節転移のメカニズム解明
• 癌進展における炎症、免疫の影響
• 人工知能および空間網羅的遺伝子発現解析を用いた乳癌の形態学的特徴に関する研究

業績

|　和文論文・著書

|　英文論文・著書

1. Sasagu Kurozumi,  Kyoichi Kaira , Hiroshi Matsumoto,  Masafumi Kurosumi , Takehiko Yokobori, Yoshikatsu Kanai, Chikako Sekine, Chikako Honda, Ayaka Katayama, Mio Furuya, Sho Shiino, Takaya Makiguchi, Nigel P Mongan, Emad A Rakha, Tetsunari Oyama, Takaaki Fujii, Ken Shirabe, Jun Horiguchi. Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Sci Rep. 2022 Feb 17;12(1):2742.
2. Chikako Honda,  Sasagu Kurozumi , Ayaka Katayama, Bishoy Hanna- Khalil, Kei Masuda, Yuko Nakazawa, Misato Ogino, Sayaka Obayashi, Reina Yajima, Takaya Makiguchi, Tetsunari Oyama, Jun Horiguchi, Ken Shirabe, Takaaki Fujii. Prognostic value of tumor-infiltrating lymphocytes in estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer. Mol Clin Oncol. 2021 Dec;15(6):252.
3. Misato Ogino, Takaaki Fujii, Yukio Koibuchi, Yuko Nakazawa, Daisuke Takata, Ken Shirabe. Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer. Anticancer Res. 2021 Aug;41(8):3899-3904.
4. Takaaki Fujii, Yuko Nakazawa, Misato Ogino, Sayaka Obayashi, Reina Yajima, Chikako Honda, Hideharu Nakamura, Takaya Makiguchi, Ken Shirabe. Oncological safety of immediate breast reconstruction with skin- or nipple-sparing mastectomy: the value of tumor-to-dermis distance measured by preoperative ultrasonography. World J Surg Oncol. 2021
5. Misato Ogino, Takaaki Fujii, Yuko Nakazawa, Toru Higuchi, Yukio Koibuchi, Tetsunari Oyama, Jun Horiguchi, Ken Shirabe. Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer. In Vivo. 2020
6. Yuko Nakazawa, Seshiru Nakazawa, Sasagu Kurozumi, Misato Ogino, Yukio Koibuchi, Hiroki Odawara, Tetsunari Oyama, Jun Horiguchi, Takaaki Fujii, Ken Shirabe. The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy. Oncol Lett. 2020
7. Takaaki Fujii, Tomoko Hirakata, Sasagu Kurozumi, Shoko Tokuda, Yuko Nakazawa, Sayaka Obayashi, Reina Yajima, Tetsunari Oyama, Ken Shirabe. VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer．In Vivo. 2020
8. Takaaki Fujii, Shoko Tokuda, Yuko Nakazawa, Sasagu Kurozumi, Sayaka Obayashi, Reina Yajima, Ken Shirabe. Relationship Between FDG Uptake and the Platelet/lymphocyte Ratio in Patients With Breast Invasive Ductal Cancer. In Vivo. 2020
9. Takaaki Fujii, Shoko Tokuda, Yuko Nakazawa, Sasagu Kurozumi, Sayaka Obayashi, Reina Yajima, Ken Shirabe. Implications of Low Serum Albumin as a Prognostic Factor of Long-term Outcomes in Patients With Breast Cancer. In Vivo. 2020
10. Takaaki Fujii, Shoko Tokuda, Yuko Nakazawa, Sasagu Kurozumi, Sayaka Obayashi, Reina Yajima, Ken Shirabe. Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer. In Vivo. 2020
11. Misato Ogino, Takaaki Fujii, Yuko Nakazawa, Toru Higuchi, Yukio Koibuchi, Tetsunari Oyama, Jun Horiguchi, Ken Shirabe. Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer. In Vivo. 2020
12. Keiko Yanai, Takaaki Fujii, Jun Horiguchi, Yuko Nakazawa, Sasagu Kurozumi, Sayaka Obayashi, Reina Yajima, Ken Shirabe. Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer. BMC Cancer. 2020
13. Sasagu Kurozumi, Mansour Alsaleem, Cíntia J. Monteiro, Kartikeya Bhardwaj, Stacey E. P. Joosten, Takaaki Fujii, Ken Shirabe, Andrew R. Green, Ian O. Ellis, Emad A. Rakha, Nigel P. Mongan, David M. Heery, Wilbert Zwart, Steffi Oesterreich, Simon J. Johnston. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Res. 2020
14. Sasagu Kurozumi, Chitra Joseph, Sultan Sonbul, Sami Alsaeed, Yousif Kariri, Abrar Aljohani, Sara Raafat, Mansour Alsaleem, Angela Ogden, Simon J Johnston, Mohammed A Aleskandarany, Takaaki Fujii, Ken Shirabe, Carlos Caldas, Ibraheem Ashankyty, Leslie Dalton, Ian O Ellis, Christine Desmedt, Andrew R Green, Nigel P Mongan, Emad A Rakha. A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. Br J Cancer. 2019
15. Sasagu Kurozumi, Hiroshi Matsumoto, Masafumi Kurosumi, Kenichi Inoue, Takaaki Fujii, Jun Horiguchi, Ken Shirabe, Tetsunari Oyama, Hiroyuki Kuwano. Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. Oncol Lett. 2019
16. Sasagu Kurozumi, Kenichi Inoue, Hiroshi Matsumoto, Takaaki Fujii, Jun Horiguchi, Tetsunari Oyama, Masafumi Kurosumi, Ken Shirabe. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Sci Rep. 2019
17. Sasagu Kurozumi, Yuri Yamaguchi, Hiroshi Matsumoto, Masafumi Kurosumi, Shin-ichi Hayashi, Takaaki Fujii, Jun Horiguchi, Ken Shirabe, Kenichi Inoue. Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy. PLoS One. 2019
18. Sasagu Kurozumi, Kenichi Inoue, Hiroshi Matsumoto, Takaaki Fujii, Jun Horiguchi, Tetsunari Oyama, Masafumi Kurosumi, Ken Shirabe. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer. Sci Rep. 2019
19. Fujii T, et al. Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer. Anticancer Res. 2018
20. Fujii T, et al. Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01). Anticancer Res 2018
21. Kurozumi S, et al. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer. Med Mol Morphol. 2018
22. Toda H, Kurozumi S, et al. Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3. J Hum Genet. 2018
23. Kurozumi S, et al. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer. PLoS One. 2018
24. Kurozumi S, et al. Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. Breast Cancer Res Treat. 2018
25. Makiguchi T, Nakamura H, Fujii T, Yokoo S. Quantitative assessment and risk factors for nipple-areolar complex malposition after nipple-sparing mastectomy. Breast Cancer. 2018
26. Kurozumi S, et al. Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. Breast Cancer Res Treat. 2018
27. Fujii T, et al. Implication of atypical supraclavicular F18-fluorodeoxyglucose uptake in patients with breast cancer: Relationship between brown adipose tissue and breast cancer progression. Oncology Letters 2017
28. Obayashi S, et al. Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. Int J Oncol 2017
29. Kurozumi S, et al. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Med Mol Morphol 2017
30. Kurozumi S, et al. Power of PgR expression as a prognostic factor for ER-positive/HER2-negatiev breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer 2017.
31. Kurozumi S, et al. Recent in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet 2017.
32. Fujii T, et al. Clinicopathological Features of Ductal Carcinoma In Situ from 18F-FDG-PET Findings. Anticancer Res 2017.
33. Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J, Kuwano H. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Med Mol Morphol. 2017
34. Fujii T, et al. 18F-fluorodeoxyglucose uptake as predictor for invasion in preoperatively diagnosed breast ductal carcinoma in situ: Significance in cases without mass formation Mol Clin Oncol 2017
35. Fujii T, et al. A case of subareolar abscess in the male breast: Usefulness of MRI for diagnosis. International Journal of Case Reports and Images 2017
36. Yajima R, et al. Tumor-infiltrating CD45RO+ memory cells are associated with a favorable prognosis breast cancer. Breast Cancer 2016.
37. Kurozumi S, et al. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat 2016.
38. Kurozumi S, et al. Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer. Cancer Med 2016.
39. Fujii T, et al. Clinicopathological features of cases with primary breast cancer not identified by 18F-FDG-PET. Anticancer Res 2016.
40. Fujii T, et al. Clincal significance of 18F-FDG-PET in invasive lobular carcinoma. Anticancer Res 2016.
41. Fujii T, et al. Implication of F18-fluorodeoxyglucose uptake of affected axillary lymph nodes in cases with differentiated thyroid cancer. Mol Clin Oncol 2016.
42. Fujii T, et al. Implications of long-term indwelling of tissue expander in breast reconstruction: risk of expander rupturing. Anticancer Res 2016.
43. Fujii T, et al. Implication of F18-fluorodeoxyglucose uptake of affected axillary lymph nodes in cases with breast cancer. Anticancer Res 2016.
44. Fujii T, et al. Prediction of extracapsular invasion at metastatic sentinel nodes and non-sentinel lymph nodal metastases by FDG-PET in cases with breast cancer. Anticancer Res 2016
45. Fujii T, et al. Anticancer effect of rapamycin on MCF-7 via downregulation of VEGF expression. In Vitro Cell Dev Biol Anim 2016.
46. Fujii T, et al. Cystic parathyroid adenoma with MIBI scan-negative PHPT: Usefulness of Gamma camera. Int J Case Rep Imag 2016.
47. Kurozumi S, et al. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. BMC Cancer 2015.
48. Fujii T, et al. Impact of vascular invasion of a primary tumor as a strong risk factor for disease recurrence in patients with node-positive breast cancer. Am Surg 2015
49. Fujii T, et al. Significance of lymphatic invasion combined with size of primary tumor for predicting sentinel lymph node metastasis in patients with breast cancer. Anticancer Res 2015
50. Fujii T, et al. Implication of duration of clinical presentation on tumor progression and the short-term recurrence in patients with early breast cancer. Mol Clin Oncol 2015
51. Yajima R, et al. Prognostic value of extracapsular invasion of axillary lymph nodes combined with peritumoral vascular invasion in patients with breast cancer. Ann Surg Oncol 2015.